• 1
    Pelus LM & Fukuda S (2008) Chemokine-mobilized adult stem cells; defining a better hematopoietic graft. Leukemia 22, 466473.
  • 2
    Wright DE, Wagers AJ, Gulati AP, Johnson FL & Weissman IL (2001) Physiological migration of hematopoietic stem and progenitor cells. Science 294, 19331936.
  • 3
    Lapidot T & Petit I (2002) Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 30, 973981.
  • 4
    Dar A, Kollet O & Lapidot T (2006) Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Exp Hematol 34, 967975.
  • 5
    Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, Liles WC, Li X, Graham-Evans B, Campbell TB et al. (2005) Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201, 13071318.
  • 6
    Larochelle A, Krouse A, Metzger M, Orlic D, Donahue RE, Fricker S, Bridger G, Dunbar CE & Hematti P (2006) AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 107, 37723778.
  • 7
    Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, Devine H, Link DC, Calandra G, Bridger G et al. (2008) Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 112, 990998.
  • 8
    Liles WC, Rodger E, Broxmeyer HE, Dehner C, Badel K, Calandra G, Christensen J, Wood B, Price TH & Dale DC (2005) Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 45, 295300.
  • 9
    Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E, Nagler A & Peled A (2007) Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells 25, 21582166.
  • 10
    Dar A, Schajnovitz A, Lapid K, Kalinkovich A, Itkin T, Ludin A, Kao WM, Battista M, Tesio M, Kollet O et al. (2011) Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells. Leukemia 25, 12861296.
  • 11
    Hegde R, Borkow G, Berchanski A & Lapidot A (2007) Structure–function relationship of novel X4 HIV-1 entry inhibitors – l- and d-arginine peptide–aminoglycoside conjugates. FEBS J 274, 65236536.
  • 12
    Lapidot A, Berchanski A & Borkow G (2008) Insight into the mechanisms of aminoglycoside derivatives interaction with HIV-1 entry steps and viral gene transcription. FEBS J 275, 52365257.
  • 13
    Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC et al. (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330, 10661071.
  • 14
    Brelot A, Heveker N, Montes M and Alizon M (2000) Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities. J Biol Chem 275, 2373623744.
  • 15
    Crump MP, Gong JH, Loetscher P, Rajarathnam K, Amara A, Arenzana-Seisdedos F, Virelizier JL, Baggiolini M, Sykes BD & Clark-Lewis I (1997) Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 16, 69967007.
  • 16
    Kofuku Y, Yoshiura C, Ueda T, Terasawa H, Hirai T, Tominaga S, Hirose M, Maeda Y, Takahashi H, Terashima Y et al. (2009) Structural basis of the interaction between chemokine stromal cell-derived factor-1/CXCL12 and its G-protein-coupled receptor CXCR4. J Biol Chem 284, 3524035250.
  • 17
    Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K & DiPersio J (2008) A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 14, 12531261.
  • 18
    Tigue CC, McKo JM, Evens AM, Trifilio SM, Tallman MS & Bennett CL (2007) Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 40, 185192.
  • 19
    Tian S, Choi WT, Liu D, Pesavento J, Wang Y, An J, Sodroski JG & Huang Z (2005) Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1alpha on CXCR4 transmembrane helical domains. J Virol 79, 1266712673.
  • 20
    Rosenkilde MM, Gerlach LO, Hatse S, Skerlj RT, Schols D, Bridger GJ & Schwartz TW (2007) Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J Biol Chem 282, 2735427365.
  • 21
    Veldkamp CT, Seibert C, Peterson FC, De la Cruz NB, Haugner JC III, Basnet H, Sakmar TP & Volkman BF (2008) Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci Signal 1, ra4, 1–9.
  • 22
    Gerlach LO, Skerlj RT, Bridger GJ & Schwartz TW (2001) Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 276, 1415314160.
  • 23
    Hatse S, Princen K, Bridger G, De Clercq E & Schols D (2002) Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 527, 255262.
  • 24
    Fricker SP, Anastassov V, Cox J, Darkes MC, Grujic O, Idzan SR, Labrecque J, Lau G, Mosi RM, Nelson KL et al. (2006) Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor CXCR4. Biochem Pharmacol 72, 588596.
  • 25
    Wong RS, Bodart V, Metz M, Labrecque J, Bridger G & Fricker SP (2008) Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol 74, 14851495.
  • 26
    Juarez J, Bradstock KF, Gottlieb DJ & Bendall LJ (2003) Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 17, 12941300.
  • 27
    Spiegel A, Kollet O, Peled A, Abel L, Nagler A, Bielorai B, Rechavi G, Vormoor J & Lapidot T (2004) Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling. Blood 103, 29002907.
  • 28
    Pettersson S, Perez-Nueno VI, Mena MP, Clotet B, Este JA, Borrel JI & Teixido J (2010) Novel monocyclam derivatives as HIV entry inhibitors: design, synthesis, anti-HIV evaluation, and their interaction with the CXCR4 co-receptor. ChemMedChem 5, 12721281.
  • 29
    Lam AR, Bhattacharya S, Patel K, Hall SE, Mao A & Vaidehi N (2011) Importance of receptor flexibility in binding of cyclam compounds to the chemokine receptor CXCR4. J Chem Inf Model 51, 139147.
  • 30
    Trent JO, Wang ZX, Murray JL, Shao W, Tamamura H, Fujii N & Peiper SC (2003) Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J Biol Chem 278, 4713647144.
  • 31
    Doranz BJ, Filion LG, Diaz-Mitoma F, Sitar DS, Sahai J, Baribaud F, Orsini MJ, Benovic JL, Cameron W & Doms RW (2001) Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res Hum Retroviruses 17, 475486.
  • 32
    Sweeney EA, Lortat-Jacob H, Priestley GV, Nakamoto B & Papayannopoulou T (2002) Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells. Blood 99, 4451.
  • 33
    Hidalgo A, Peired AJ, Weiss LA, Katayama Y & Frenette PS (2004) The integrin alphaMbeta2 anchors hematopoietic progenitors in the bone marrow during enforced mobilization. Blood 104, 9931001.
  • 34
    Albanese P, Caruelle D, Frescaline G, Delbe J, Petit-Cocault L, Huet E, Charnaux N, Uzan G, Papy-Garcia D & Courty J (2009) Glycosaminoglycan mimetics-induced mobilization of hematopoietic progenitors and stem cells into mouse peripheral blood: structure/function insights. Exp Hematol 37, 10721083.
  • 35
    Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Ponomaryov T, Taichman RS, Arenzana-Seisdedos F, Fujii N et al. (2002) G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3, 687694.
  • 36
    Kalinkovich A, Tavor S, Avigdor A, Kahn J, Brill A, Petit I, Goichberg P, Tesio M, Netzer N, Naparstek E et al. (2006) Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells. Cancer Res 66, 1101311020.
  • 37
    Berchanski A & Lapidot A (2007) Prediction of HIV-1 entry inhibitors neomycin–arginine conjugates interaction with the CD4-gp120 binding site by molecular modeling and multistep docking procedure. Biochim Biophys Acta 1768, 21072119.
  • 38
    Berchanski A & Lapidot A (2009) Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites. J Mol Model 15, 281294.
  • 39
    Heifetz A, Katchalski-Katzir E & Eisenstein M (2002) Electrostatics in protein–protein docking. Protein Sci 11, 571587.
  • 40
    Berchanski A, Shapira B & Eisenstein M (2004) Hydrophobic complementarity in protein–protein docking. Proteins 56, 130142.
  • 41
    Honig B & Nicholls A (1995) Classical electrostatics in biology and chemistry. Science 268, 11441149.